MedTrace Logo

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

NCT00507429 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).

Conditions

  • Anaplastic Thyroid Cancer

Interventions

DRUG

CA4P

CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles

DRUG

paclitaxel

200mg/m squared on Day 1

DRUG

carboplatin

6 AUC on Day 1 following paclitaxel

Sponsors & Collaborators

  • Mateon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Julie A. Sosa, MD, FACS · Yale University School of Medicine, New Haven, CT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States
  • Belarus
  • Bulgaria
  • Egypt
  • India
  • Israel
  • Italy
  • Poland
  • Romania
  • Russia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00507429 on ClinicalTrials.gov